Knight Therapeutics (OTCMKTS:KHTRF) Share Price Down 2.3% – Time to Sell?

Knight Therapeutics Inc stock price (OTCMKTS:KHTRF – Get a Free Report ) was down 2.3% on Wednesday. The stock traded as high as $4.26 and last traded at $4.26. 400 shares traded hands during mid-day trading, down 92% from the session’s average volume of 5,277 shares. Shares previously closed at $4.36.

Knight Therapeutics trading down 2.3%

The stock has a 50-day moving average price of $4.23 and a 200-day moving average price of $4.20.

About Knight Therapeutics

(Get a free report)

Knight Therapeutics Inc develops, manufactures, acquires, licenses, out-licenses, markets and distributes consumer healthcare and pharmaceutical products and medical devices worldwide. Offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for the prevention of acute and delayed chemotherapy-induced nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for advanced adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxan for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and differentiated thyroid cancer and unresectable hepatocellular carcinoma.

Featured stories

Get news and reviews for Knight Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Knight Therapeutics and related companies with MarketBeat.com ‘s FREE daily newsletter.